Connect with us
  • tg

Stock Markets

Hillman Solutions Corp. enacts governance changes

letizo News

Published

on

CINCINNATI, OH – Hillman Solutions Corp. (NASDAQ:HLMN), a company specializing in cutlery, handtools, and general hardware, has announced significant amendments to its corporate governance structure following approval from its stockholders. In a recent SEC filing, the company stated that during its Annual Meeting held on Thursday, June 7, 2024, several key changes were ratified that will affect how the company is governed moving forward.

The approved amendments include the decision to declassify the Board of Directors by the 2027 annual meeting, which will transition the board from staggered terms to all directors being elected annually. This move is seen as a step towards greater accountability and responsiveness to shareholders. Additionally, the amendments eliminate the requirement for a supermajority vote when amending the company’s Certificate of Incorporation and Bylaws, simplifying the process for future governance changes

In other recent news, hardware and technology firm Hillman Solutions reported a slight increase in net sales to $350.3 million and a significant 30% rise in adjusted EBITDA to $52.3 million in its Q1 2024 earnings call. Despite a mixed performance across segments and macroeconomic challenges, Hillman remains committed to its growth strategy. The company noted a 2.4% increase in net sales in the Hardware and Protective Solutions segment, while the Robotics & Digital Solutions segment saw a 9.2% decline.

In a recent development, Hillman acquired Koch Industries and is currently evaluating seven companies for potential acquisitions. The firm’s full-year guidance remains unchanged, with net sales projected between $1.475 billion to $1.555 billion and adjusted EBITDA between $230 million to $240 million.

Hillman anticipates a net leverage ratio of around 2.7 times by the end of 2024 and is actively pursuing strategic M&A opportunities. The company is also focusing on new kiosk market partnerships and expects to maintain gross margins above 45%, despite price reductions. These recent developments suggest Hillman is poised for continued growth amidst challenges.

InvestingPro Insights

In light of Hillman Solutions Corp.’s (NASDAQ:HLMN) recent governance changes, a glance at the company’s financial health and market performance offers additional context for investors. According to InvestingPro data, Hillman Solutions has a market capitalization of $1.75 billion, with a high P/E ratio last twelve months as of Q1 2024, reflecting investor expectations of future earnings growth. This is supported by one of the InvestingPro Tips, which indicates that net income is expected to grow this year, and analysts have revised their earnings upwards for the upcoming period. Additionally, the company’s liquid assets exceed its short-term obligations, suggesting financial stability in the near term.

While the company has not been profitable over the last twelve months, analysts predict profitability this year, adding a positive outlook to the governance changes intended to enhance shareholder value. It’s worth noting that Hillman Solutions does not pay a dividend, which may influence investment strategies focused on income. For investors interested in deeper analysis, there are additional InvestingPro Tips available, and they can access these by using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Stock Markets

BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures – Hagens Berman

letizo News

Published

on

San Francisco, California–(Newsfile Corp. – December 25, 2024) – On December 9, 2024, just months after conducting an initial public offering in September 2024, BioAge Labs, Inc. (NASDAQ: BIOA) made the startling announcement that it was discontinuing a Phase 2 study for its lead product, azelaprag, intended to treat metabolic diseases such as obesity.

Hagens Berman has opened an investigation and urges investors in BioAge who purchased shares in the company’s IPO or on the open market and suffered substantial losses to submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/bioa
Contact the Firm Now: BIOA@hbsslaw.com
844-916-0895

BioAge Labs, Inc. (BIOA) Investigation:

The investigation is focused on the propriety of BioAge’s disclosures about the safety data and other matters related to azelaprag, which the company said in its IPO documents has been “well-tolerated in 265 individuals across eight Phase 1 clinical trials.”

BioAge’s disclosures came into question after the market closed on December 6, 2024, when the company announced the discontinuation of the STRIDES Phase 2 clinical trial evaluating azelaprag in combination with tirzepatide for the treatment of obesity. BioAge said that liver transaminitis was observed in patients receiving azelaprag.

This news drove the price of BioAge shares down almost 80% on December 9, 2024.

“We’re focused on whether BioAge was transparent to investors about the azelaprag safety profile before the December 6 announcement,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in BioAge and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the BioAge investigation, read more »

Whistleblowers: Persons with non-public information regarding BioAge should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email BIOA@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235182

Continue Reading

Stock Markets

Celsius Holdings (CELH) Hit with Investor Class Action Amid Accusations of Oversold Inventory to Pepsi- Hagens Berman

letizo News

Published

on

CELH Investors with Losses Encouraged to Contact the Firm

San Francisco, California–(Newsfile Corp. – December 25, 2024) – Celsius Holdings (NASDAQ:), Inc. (NASDAQ: CELH) and certain of its C-Suite officers are embroiled in a securities class action lawsuit, claiming they misrepresented and concealed crucial information about the company’s financial performance, especially concerning its key customer, PepsiCo (NASDAQ:).

Hagens Berman is investigating the allegations and urges investors in Celsius who purchased shares and suffered substantial losses to submit your losses now.

Class Period: Feb. 29, 2024 – Sept. 4, 2024
Lead Plaintiff Deadline: Jan. 21, 2025
Visit: www.hbsslaw.com/investor-fraud/celh
Contact the Firm Now: CELH@hbsslaw.com
844-916-0895

Celsius Holdings, Inc. (CELH) Securities Class Action (WA:):

The lawsuit alleges that during the Class Period, Celsius failed to disclose to investors several critical points:

  1. Oversold Inventory: Celsius significantly oversold inventory to Pepsi beyond demand, leading to a potential drastic reduction in future purchases.
  2. Declining Sales: As Pepsi depleted its overstock, Celsius’ sales were projected to decline, impacting its financial health and outlook.
  3. Unsustainable Sales Rates: The sales rates to Pepsi were unsustainable and created a misleading impression of the company’s performance.
  4. Misleading Metrics: Consequently, Celsius’ business metrics and financial prospects were overstated

The situation came to light on May 28, 2024, when Celsius’ stock price plummeted nearly 13% following reports from Nielsen indicating slowed sales growth. Analysts highlighted the possibility of significantly reduced sales as Pepsi cut back its inventory.

The stock took another hit on September 4, 2024, dropping over 11% after a company presentation revealed a shortfall of $100 million to $120 million in Pepsi orders compared to the previous year. It was also disclosed that Pepsi had held several million excess cases over the last 18 months.

These revelations have led shareholder rights firm Hagens Berman to investigate the allegations.

“We’re investigating whether Celsius deliberately painted an overly optimistic picture of its relationship with Pepsi, misleading investors about the true state of its financial health and sales sustainability,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Celsius and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the Celsius case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Celsius Holdings should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email CELH@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235180

Continue Reading

Stock Markets

Suriname fugitive ex-President Desi Bouterse dead at 79

letizo News

Published

on

By Ank Kuipers

PARAMARIBO (Reuters) -Suriname’s fugitive former President Desi Bouterse has died aged 79, the country’s government said on Wednesday, almost a year after he fled authorities to avoid jail following his conviction over the murder of 15 political activists in 1982.

“The government has been informed through the family and its own investigations of the passing of Mr. D. Bouterse, ex-President of the Republic of Suriname,” Foreign Minister Albert Ramdin told Reuters.

The former leader died on Tuesday, the government said, without confirming where, or even in which country. Last week Surinamese authorities raided his home – where supporters gathered to pay their respects on Wednesday morning – but did not find him.

Surinamese President Chan Santokhi, who investigated the case as a police commissioner and later as justice minister, expressed condolences to Bouterse’s family and urged calm in a statement.

“In the spirit of the holiday season and year-end, the president calls on all to remain dignified and calm, maintain peace and order and engage in prayer in the spirit of these special days,” the statement said.

Bouterse dominated politics in the tiny South American country for decades, leading a coup in 1980 and finally leaving office in 2020.

In 2019 he and six others were convicted for their role in the 1982 murders of 15 leading government critics – including lawyers, journalists, union leaders, soldiers and university professors – for which Bouterse received a 20-year prison sentence. 

Bouterse had claimed the murdered men were connected to a planned invasion of the former Dutch colony. 

Following years of legal back and forth, Bouterse was ordered to report to prison in January but he did not show up on the appointed date.

Though Bouterse avoided prison by going on the run, Reed Brody, a U.S. war crimes prosecutor who monitored the case for the International Commission of Jurists, said justice had caught up with the convicted former president before he died.

© Reuters. FILE PHOTO: Former Suriname president Desi Bouterse speaks during a news conference in Paramaribo, Suriname August 31, 2021. REUTERS/Ranu Abhelakh/File Photo

“Thanks to the victims’ relatives and their supporters who never gave up, Bouterse will go down in history as a convicted murderer,” Brody said.

The former president’s family will make a statement later on Wednesday, members of his political party told journalists. 

Continue Reading

Trending

©2021-2024 Letizo All Rights Reserved